晚期肛门鳞状细胞癌的新一线选择

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-07-01 DOI:10.1038/s41571-025-01056-4

Diana Romero

{"title":"晚期肛门鳞状细胞癌的新一线选择","authors":"Diana Romero","doi":"10.1038/s41571-025-01056-4","DOIUrl":null,"url":null,"abstract":"The combination of carboplatin plus docetaxel is the standard-of-care first-line treatment for patients with anal squamous cell carcinoma (ASCC) in the recurrent or metastatic setting, although this regimen provides limited survival benefit and quality of life remains poor. Now, results from the phase III POD1UM-303/InterAACT-2 trial demonstrate the efficacy and safety of adding the anti-PD-1 antibody retifanlimab to first-line chemotherapy in this setting.A total of 308 patients with locally recurrent or metastatic ASCC were randomly allocated (1:1) to receive first-line carboplatin–docetaxel (6 cycles) plus either retifanlimab or placebo for up to 1 year. Progression-free survival (PFS) was the primary end point.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"47 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new first-line option for advanced-stage anal squamous cell carcinoma\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-025-01056-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The combination of carboplatin plus docetaxel is the standard-of-care first-line treatment for patients with anal squamous cell carcinoma (ASCC) in the recurrent or metastatic setting, although this regimen provides limited survival benefit and quality of life remains poor. Now, results from the phase III POD1UM-303/InterAACT-2 trial demonstrate the efficacy and safety of adding the anti-PD-1 antibody retifanlimab to first-line chemotherapy in this setting.A total of 308 patients with locally recurrent or metastatic ASCC were randomly allocated (1:1) to receive first-line carboplatin–docetaxel (6 cycles) plus either retifanlimab or placebo for up to 1 year. Progression-free survival (PFS) was the primary end point.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"47 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01056-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01056-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

卡铂联合多西他赛是复发或转移性肛门鳞状细胞癌（ASCC）患者的标准一线治疗方案，尽管该方案提供的生存益处有限，生活质量仍然很差。现在，III期POD1UM-303/InterAACT-2试验的结果表明，在这种情况下，在一线化疗中添加抗pd -1抗体retifanlimab的有效性和安全性。共有308例局部复发或转移性ASCC患者被随机分配（1:1），接受一线卡铂-多西他赛（6个周期）加利替利单抗或安慰剂治疗长达1年。无进展生存（PFS）是主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A new first-line option for advanced-stage anal squamous cell carcinoma

The combination of carboplatin plus docetaxel is the standard-of-care first-line treatment for patients with anal squamous cell carcinoma (ASCC) in the recurrent or metastatic setting, although this regimen provides limited survival benefit and quality of life remains poor. Now, results from the phase III POD1UM-303/InterAACT-2 trial demonstrate the efficacy and safety of adding the anti-PD-1 antibody retifanlimab to first-line chemotherapy in this setting.

A total of 308 patients with locally recurrent or metastatic ASCC were randomly allocated (1:1) to receive first-line carboplatin–docetaxel (6 cycles) plus either retifanlimab or placebo for up to 1 year. Progression-free survival (PFS) was the primary end point.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.